**Whole-Cell versus Acellular Pertussis Vaccines: A Comparative Review of Immunogenicity, Safety, Efficacy, and the Concept of "Painless" Vaccination**

**1. Introduction**

Childhood immunization is crucial for preventing vaccine-preventable diseases, significantly reducing morbidity and mortality [1]. However, vaccine-related pain and distress are common concerns for parents and caregivers, contributing to vaccine hesitancy and delays in immunizations [2]. In response, "painless" acellular pertussis (aP) vaccines were developed, offering reduced post-vaccination reactions compared to whole-cell pertussis (wP) vaccines. However, the term "painless" refers primarily to decreased reactogenicity (e.g., fever, swelling) rather than the complete absence of injection pain [3, 4]. This paper critically compares the immunogenicity, safety, efficacy, and duration of protection of wP and aP vaccines, considering the trade-offs in immunity and reactogenicity.

**2. Vaccine Composition and Immunological Mechanisms**

The key difference between DTwP and DTaP vaccines lies in their pertussis components:

* **Whole-Cell Pertussis (wP) Vaccines**: Contain the entire inactivated Bordetella pertussis bacterium, retaining its natural antigens and structural components, including **Lipopolysaccharide (LPS)**, a potent endotoxin found in the outer membrane of the bacterium [5, 6]. LPS plays a critical role in immune modulation by activating innate immune cells (e.g., dendritic cells, macrophages) via Toll-like receptor 4 (TLR4), triggering pro-inflammatory cytokines and strong T-cell responses (Th1 and Th17 pathways) [6, 8, 9]. This response mimics natural infection, contributing to potent, durable immunity [9]. The adjuvant properties of LPS reduce the need for additional adjuvants like aluminum salts, though some wP formulations may still include them [5, 6].
* **Acellular Pertussis (aP) Vaccines**: Contain purified components of B. pertussis, typically **pertussis toxin (PT)** and other antigens such as **filamentous hemagglutinin (FHA)**, **pertactin (PRN)**, and **fimbriae (FIM2/3)**, but lack LPS [3, 7]. The number of components can vary between licensed aP vaccines, ranging from one to five [7].

**Immunological Response**:

* **wP**: LPS induces a strong innate immune activation, leading to robust T-cell responses (Th1 and Th17), which contribute to long-lasting immunity [6, 8, 9].
* **aP**: Lacking LPS and other immune activators, aP vaccines rely on added adjuvants like **aluminum salts** to enhance immunogenicity [3, 7]. This typically induces a strong antibody response but favors a **Th2-dominant** immune response (IL-4, IL-5, IL-13), with less pronounced Th1 and Th17 components compared to wP [8, 9]. This may explain the differences in the quality and duration of immunity between the two vaccine types [10].


| **Feature** | **Whole-cell Pertussis (wP)** | **Acellular Pertussis (aP)** |
| --- | --- | --- |
| Pertussis Component | Entire inactivated B. pertussis bacterium [5] | Purified components like PT, FHA, PRN, FIM2/3 [3, 7] |
| LPS (Lipopolysaccharide) | Present – acts as a strong immune stimulant [6] | Absent – lacks PAMPs like LPS [3, 7] |
| Adjuvant Use | Intrinsic LPS acts as a natural adjuvant; some formulations may include aluminum salts [5, 6] | Requires added adjuvants like aluminum hydroxide or phosphate [3, 7] |
| Immune Activation | Strong innate activation via TLR4 → robust Th1 + Th17 response [6, 8, 9] | Weaker innate activation → primarily Th2 antibody response; limited Th17 [8, 9, 10] |
| Immunity Quality | Mimics natural infection; long-lasting cellular and humoral immunity [9] | Effective antibody generation, but immunity wanes faster [10] |

**3. Safety and Reactogenicity Comparison**

| **Side Effect** | **Whole-cell Pertussis (wP)** | **Acellular Pertussis (aP)** |
| --- | --- | --- |
| Fever | High frequency [4, 6, 11] | Low frequency [3, 4, 11] |
| Injection Site Swelling | Moderate to severe; may involve entire limb [4, 11] | Mild and localized [3, 4, 11] |
| Irritability / Prolonged Crying | Common and sometimes prolonged [4, 11] | Less frequent and shorter duration [3, 4, 11] |
| Febrile Seizures | Rare; higher relative risk but low absolute incidence [4, 12] | Very rare; lower relative risk [4, 12] |
| Hypotonic-Hyporesponsive Episodes (HHE) | Reported rarely [11] | Extremely rare [11] |
| Long-term Neurological Risks | No proven risk; large studies refuted earlier concerns [12, 13] | No evidence of serious long-term harm [12, 13] |
| SAE Summary | Excellent overall safety |  |

Reactogenicity encompasses the common, expected, and generally mild-to-moderate short-term reactions following vaccination, largely reflecting the innate inflammatory response.

* **Reactogenicity**: DTwP vaccines are associated with higher frequency and intensity of common reactions such as fever, redness, swelling, drowsiness, fussiness, and prolonged crying compared to DTaP vaccines. This heightened reactogenicity is mainly due to the pro-inflammatory effects of **LPS** and other components in the whole-cell preparation, which activate innate immune pathways [4, 6, 11]. DTaP vaccines, with lower antigenic load and lacking LPS, generally cause milder and less frequent reactions [3, 4, 11].



* **Serious Adverse Events (SAEs)**: Both wP and aP vaccines have excellent safety profiles regarding rare adverse events. Large-scale studies confirm that while DTaP vaccines have a slightly lower relative risk for events like high fever, febrile seizures, and hypotonic-hyporesponsive episodes (HHE), the absolute risk is extremely low for both vaccine types [3, 4, 11, 12]. Concerns about wP causing permanent neurological damage have been refuted by extensive studies [12, 13]. Moreover, combination vaccines (e.g., Hexavalent) do not increase the risk of SAEs [11, 13].

While the term "painless" vaccine refers to reduced reactogenicity, it is a misnomer for the injection process itself, but it accurately reflects fewer common side effects associated with aP vaccines compared to wP.

**4. Efficacy and Duration of Protection**

While safety is paramount, the ultimate goal of vaccination is effective and durable protection against disease.

* **Initial Efficacy**: Both aP and wP vaccines demonstrate high efficacy against pertussis in the first 1-2 years following primary immunization [3, 4, 11, 14]. While some studies suggest slightly higher initial efficacy for wP in certain settings, updated reviews confirm high efficacy for both vaccines [10, 11].
* **Duration of Protection**: Immunity from wP vaccines lasts significantly longer, often exceeding a decade, while aP immunity wanes considerably faster, typically within 4-7 years after the last dose, requiring additional boosters [9, 10, 16, 18]. Studies show substantial annual waning rates after the 5th DTaP dose [18].
* **Impact on Transmission**: wP vaccines may be more effective in preventing not just disease but also B. pertussis infection and transmission, contributing to stronger herd immunity. The switch to aP vaccines, with faster immunity decline, has been linked to pertussis resurgence in some regions, though multiple factors contribute to this trend [10, 18, 20]. Ongoing research continues to explore the impact of vaccination on transmission.

**5. Discussion and Recommendations**

The choice between wP and aP vaccines presents a public health dilemma: balancing the reduced short-term reactogenicity of aP vaccines against the need for robust, long-lasting immunity and better disease transmission control offered by wP vaccines [3, 4, 11]. While aP vaccines are advantageous in reducing common side effects, this comes at the cost of faster immunity waning, requiring continuous booster doses [16, 18]. This necessitates complex vaccination schedules in settings using only aP vaccines [15, 20].

Recognizing this trade-off, global and national health organizations provide specific guidance:

* **World Health Organization (WHO)**: The 2015 WHO position paper recommends continuing the use of wP vaccines for primary infant immunization. Ongoing work by WHO advisory groups (e.g., SAGE) continues to refine recommendations on pertussis control, including booster strategies and maternal immunization [15].
* **Indian Academy of Pediatrics (IAP)**: The IAP (2020-2021) prefers DTwP over DTaP for primary vaccination due to its superior immunogenicity, longer protection, and better herd immunity, despite higher reactogenicity. DTaP is considered for specific situations [21].

The resurgence of pertussis highlights the importance of sustained population immunity. While the switch to aP vaccines has contributed to this, other factors such as waning immunity, pathogen adaptation, and improved surveillance also play significant roles. Ultimately, the reduced discomfort of aP vaccines must be weighed against the long-term immunity and disease control benefits of wP vaccines, especially for primary immunization.

**6. Conclusion**

The term "painless vaccine," applied to pertussis immunization, refers to acellular (aP) formulations (DTaP) causing significantly fewer common post-vaccination reactions compared to whole-cell (wP) counterparts (DTwP), largely due to the absence of LPS. However, updated evidence confirms this reduced reactogenicity is associated with less durable immunity requiring booster doses. Both vaccine types have excellent safety profiles regarding rare serious adverse events. Given the superior longevity of protection conferred by wP vaccines, the WHO's foundational position (2015, with ongoing refinements) and current national guidelines like India's IAP (2025) continue to recommend effective wP vaccines for primary infant series where established. The decision requires evaluating the trade-off between short-term reactogenicity and achieving sustained, long-term population protection against pertussis. Consulting the most recent systematic reviews and guidelines is essential for current decision-making.

**7. References**

1. World Health Organization. Immunization Agenda 2030: A Global Strategy to Leave No One Behind. Geneva: WHO; 2020.
2. Taddio A, Appleton M, Bortolussi R, et al. Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.1 *CMAJ*. 2010;182(18):E843-E855.
3. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. *N Engl J Med*. 2011;365(4):341-351.

###### Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014 Sep 17;2014(9):CD001478. doi: 10.1002/14651858.CD001478.pub6. PMID: 25228233; PMCID: PMC9722541.

1. Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. *Plotkin's Vaccines*. 8th ed. Elsevier; 2023.
2. Ross PJ, Sutton P, Choo S. The biology of lipopolysaccharide. *Nat Rev Microbiol*. 2004;2(9):719-732.
3. Edwards KM, Decker MD. Pertussis Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. *Plotkin's Vaccines*. 8th ed. Elsevier; 2023: Chapter 31.
4. Ross PJ, Lavelle EC, Mills KHG, Boyd AP. Acellular pertussis vaccines: Balancing safety and immunity. *Trends Mol Med*. 2013;19(4):232-240.
5. Mills KHG, Ross PJ, Allen AC, Wilk MM. Do we need Th1/Th17-inducing vaccines for optimal control of *Bordetella pertussis*? *Future Microbiol*. 2014;9(7):847-862.

###### Szwejser-Zawislak E, Wilk MM, Piszczek P, Krawczyk J, Wilczyńska D, Hozbor D. Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity. Vaccines (Basel). 2022 Dec 20;11(1):1. doi: 10.3390/vaccines11010001. PMID: 36679846; PMCID: PMC9863224.

1. World Health Organization. (2014). Global vaccine safety. In *Essential Medicines & Health Products*. https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/dtp-vaccine-rates-information-sheet.pdf
2. Moore DL, Le Saux N, Scheifele D, Halperin SA; Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active (IMPACT). Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. *Pediatr Infect Dis J*. 2004;23(6):568-571.2
3. Institute of Medicine (US) Committee to Review Adverse Effects of Vaccines. Adverse Effects of Vaccines: Evidence and Causality. Washington (DC): National Academies Press3 (US); 2012.
4. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. *Pediatrics*. 2006;118(3):978-984.
5. World Health Organization. Pertussis vaccines: WHO position paper - August 2015. *Wkly Epidemiol Rec*. 2015;90(35):433-460.
6. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. *N Engl J Med*. 2012;367(11):1012-1019.5

##### Chen Z, He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017 Apr 3;13(4):744-756. doi: 10.1080/21645515.2016.1259780. Epub 2017 Jan 3. PMID: 28045580; PMCID: PMC5404361.

##### Rane MS, Rohani P, Halloran ME. Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington. Vaccine. 2021 Oct 1;39(41):6144-6150. doi: 10.1016/j.vaccine.2021.08.070. Epub 2021 Sep 4. PMID: 34493409; PMCID: PMC9665886.

1. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and8 transmission in a nonhuman primate model. *Proc Natl Acad Sci U S A*. 2014;111(2):787-792.9
2. Cherry JD. Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. *N Engl J Med*. 2012;367(9):785-787.

###### ACVIP. (2020). Q A FOR PARENTS. https://iapindia.org/pdf/vaccine-information/DPT-VACCINES.pdf

**Infographic Suggestion 1: Vaccine Composition & Immune Response**

* **Title:** How They Work: Whole-Cell vs. Acellular Pertussis Vaccines
* **Visual Concept:** A clear side-by-side comparison.
  + **Left Side (wP):** Icon of a whole (inactivated) bacterium. Key points listed: "Contains Whole *B. pertussis*", "Includes LPS (Natural Immune Booster)". Arrow pointing to icons representing a strong Th1/Th17 immune response (T-cells, interferon). Tagline: "Broader, Cell-Focused Immunity".
  + **Right Side (aP):** Icons of select protein antigens (e.g., PT, FHA, PRN). Key points listed: "Contains Purified Proteins Only", "Requires Added Adjuvant (Aluminum)". Arrow pointing to icons representing a strong Th2 immune response (Antibodies). Tagline: "Specific, Antibody-Focused Immunity".

**Infographic Suggestion 2: Side Effects: What to Expect**

* **Title:** Reactogenicity: Common Reactions vs. Rare Events
* **Visual Concept:** A bar chart comparing common, short-term side effects for DTwP vs. DTaP (e.g., Fever >38°C, Large Local Swelling, Persistent Crying). Use distinct colours and show significantly higher bars for DTwP. Include *approximate percentage ranges* reflecting current understanding from recent large studies or systematic reviews (e.g., DTwP Fever: 30-50% vs DTaP Fever: 10-20% - *Note: Actual %s should be from the latest cited source like an updated Cochrane review [4]*). **Crucially, add a prominent, separate box:** "VERY RARE RISKS: Serious events (like seizures, HHE) happen <1 in 100,000s of doses for BOTH vaccine types. Both DTwP and DTaP have excellent safety records regarding serious events.

**Infographic Suggestion 3: Immunity Lifespan: Staying Protected**

* **Title:** How Long Does Pertussis Protection Last?
* **Visual Concept:** A line graph tracking "Vaccine Effectiveness (%)" on the Y-axis against "Years Since Last Dose" on the X-axis (e.g., 0-15 years).
  + **wP Line:** Starts high (>90%) and shows a very slow, gradual decline over 10-15+ years.
  + **aP Line:** Starts high (>85-90%) but shows a steep decline starting around year 4-5, falling significantly by year 7-10.
  + **Annotations:** Add icons along the aP timeline indicating the need for booster doses (e.g., arrow at ~Age 4-6, arrow at Adolescence, icon for Maternal/Pregnancy vaccination)

**Infographic Suggestion 4: The Pertussis Puzzle: Why Does it Persist?**

* **Title:** Understanding Pertussis Today: It's Complicated
* **Visual Concept:** A central circle labeled "Pertussis Challenges". Several connecting pieces or incoming arrows labeled with contributing factors: "Waning Immunity (esp. aP)", "Vaccine Coverage Gaps", "Changes in *B. pertussis*?", "Better Diagnosis & Reporting", "aP Vaccine: Less Impact on Spread?". Include a small inset diagram comparing potential impact: "aP: Protects Lungs (Disease)" vs "wP/Natural: Protects Lungs & Nose (Disease + Colonization?)".

**Infographic Suggestion 5: The Choice: Weighing Vaccine Factors**

* **Title:** DTwP vs. DTaP: Key Considerations
* **Visual Concept:** A balance scale.
  + **Left Pan (DTaP):** Label "Acellular (aP)". Icons: Smiling baby, thermometer showing normal temp. Text bullet points: "✓ Fewer common side effects (fever, swelling)", "✕ Shorter-lasting immunity", "✕ Requires more boosters".
  + **Right Pan (DTwP):** Label "Whole-Cell (wP)". Icons: Clock showing long duration, strong shield icon. Text bullet points: "✕ More common side effects", "✓ Longer-lasting immunity", "✓ Potentially better community protection?".